Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a8/e9/5f/a8e95f8b-aa1d-fc10-a97d-970ed536395a/mza_6256469873985417328.jpg/600x600bb.jpg

Community Health Media

15 episodes

6 days ago

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Medicine

Health & Fitness

RSS

All content for Community Health Media is the property of Community Health Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/42498441/42498441-1763454552194-9cc05fdb37a7b.jpg

Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection

Community Health Media

32 minutes 57 seconds

1 month ago

Dr. Jason Mouabbi, Dr. Irene Kang, and Dr. Ruemu Birhiray - HER2+ Early Breast Cancer: Beyond pCR and Toward Brain Protection

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain?

In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS-active strategies, and how upcoming trials like DESTINY-Breast05 and COMPASS-HER2 RD could redefine the adjuvant landscape.

Watch to understand what’s next for HER2+ disease — and how oncologists are rethinking long-term protection beyond pathologic complete response.

📺 Subscribe to Community Health Media for more expert-led oncology conversations.

🎧 Stream the full episode on Spotify, Apple Podcasts, or YouTube.

#BreastCancer #HER2Positive #Oncology #BreastCancerResearch #BreastCancerAwareness #Neratinib #Trastuzumab #CancerCare #MedicalOncology #CancerResearch #CHM #CommunityHealth #Podcast #ClinicalOncology #AdjuvantTherapy #CancerEducation

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media